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also correlated with poor survival (p = 0.018). An increased 
number of IL-17+ cells were significantly correlated with 
the absence of vaso-invasion (p = 0.001), smaller tumor size 
(p = 0.030) and less infiltration depth (p = 0.021). These 
results suggest that Tregs and IL-17+ cells represent a ben-
eficial immune response, whereas Th17 cells might represent a 
poor response in cervical adenocarcinoma. This contrasts with 
the correlations described in squamous cell carcinoma, sug-
gesting that the local immune response in cervical adenocarci-
noma contributes differently to tumor growth than in squamous 
cell carcinoma.
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Tumor microenvironment · Treg · Th17 · IL-17
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BSA  Bovine serum albumin
CI  Confidence interval
CXCR  CXC chemokine receptor
EDTA  Ethylenediaminetetraacetic acid
EGFR  Epidermal growth factor receptor
FFPE  Formalin-fixed, paraffin-embedded
HPV  Human papillomavirus
IL  Interleukin
PBS  Phosphate-buffered saline
TGF-β  Transforming growth factor-β
Th  T helper
TNM  Tumor lymph node metastasis stage
Treg  Regulatory T cell
Introduction
Cervical cancer is the second leading cause of cancer 
death in young women worldwide [1]. The majority of 
Abstract Cervical adenocarcinoma comprises approximately 
15 % of cervical cancer cases. This histological subtype has 
different characteristics than cervical squamous cell carcinoma, 
which may influence disease progression. To study whether the 
infiltration of T cell subpopulations was correlated with cervi-
cal adenocarcinoma patient survival, similar to squamous cell 
carcinoma, the tumor-infiltrating T cells, Tregs, Th17 cells and 
IL-17+ cell frequencies were analyzed in a cohort of cervical 
adenocarcinoma patients (n = 67). Intraepithelial, stromal and 
total cell frequencies were scored using triple immunofluores-
cence. The majority of Tregs were present in the tumor stroma, 
while other T cells and IL-17+ cells infiltrated the tumor epi-
thelium three times more frequently. A high total number of 
Tregs were significantly correlated with improved disease-spe-
cific and disease-free survival (p = 0.010, p = 0.007). Within 
the tumor epithelium, a high T cell frequency was significantly 
correlated with improved disease-free survival (p = 0.034). In 
particular, a low number of both Tregs and IL-17+ cells were 
correlated with poor disease-specific survival (p = 0.007). A 
low number of Tregs combined with Th17 cells present were 
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cervical cancer cases can histologically be divided into 
squamous cell carcinoma (~75 % of cases), adenocarci-
noma and adenosquamous carcinoma (together 20–25 % 
of cases) [2]. Several studies have reported that the prog-
nosis for patients with cervical adenocarcinoma is worse 
than for squamous cell carcinoma [3–8], although this is 
still controversial [9, 10]. Additionally, although the over-
all incidence of cervical cancer has declined in developed 
countries as a result of cytological screening programs, 
the incidence of adenocarcinoma has remained stable or 
even increased, predominantly in young women [11, 12]. 
Cervical adenocarcinoma differs from squamous cell 
carcinoma in growth pattern, molecular background and 
sensitivity to radio- and chemotherapy [13–15]. However, 
because of the lower incidence, extensive analyses have 
been lacking.
Since practically all cases of cervical cancer are caused 
by a persistent infection with high-risk human papilloma-
virus (HPV) [16], immunosurveillance plays a critical role. 
Most cervical HPV infections are cleared in over 90 % of 
cases within 2 years [17]. In case of tumor progression, the 
immune response is thought to contribute to tumor devel-
opment rather than eradication [18]. The type and number 
of immune cells present in the tumor microenvironment are 
both crucial for clinical outcome. T helper 1 (Th1) cells 
are required to overcome intracellular pathogens and can 
induce or stimulate a tumor-targeting immune response. 
Th2 cells protect against extracellular pathogens and have 
been shown to support cervical cancer progression [19], 
but their role in cancer has not been fully elucidated. Th17 
cells are essential to protect against extracellular patho-
gens and play a dominant role in autoimmune diseases 
[20, 21]. Their role in cancer is unclear, since they have 
been shown both to be able to promote and to counteract 
tumor growth [22]. Regulatory T cells (Tregs) suppress the 
activity of other T cells [23], which may dampen either a 
tumor-suppressing or tumor-promoting immune response. 
In particular, the potentially different role of the immune 
response in squamous versus adenocarcinoma has not been 
thoroughly studied, although there are indications for dif-
ferences between the subtypes [24].
We have shown before that Tregs are more frequently 
present in cervical squamous cell carcinoma than adeno-
carcinoma and that these cells, relative to cytotoxic T 
cells, were correlated with poor survival in a representa-
tive cohort of cervical cancer patients, i.e., predominantly 
squamous cell carcinoma cases (77 %) [25]. In addition, we 
have recently shown that Th17 cells were correlated with 
improved survival in a cohort of squamous cell carcinoma 
patients [26]. Strikingly, interleukin-17 (IL-17) was pre-
dominantly expressed by neutrophils and correlated with 
poor survival in the same cohort [26].
The aim of this study was to determine the number of 
intraepithelial, stromal and total T cells, Tregs, Th17 and 
other IL-17+ cells. The correlations between the different 
cell frequencies and patient survival in cervical adenocar-
cinoma were analyzed. The contrasts with the correlations 
described in cervical squamous cell carcinoma and other 
cancer types are discussed.
Materials and methods
Patient material
Formalin-fixed, paraffin-embedded (FFPE) cervical ade-
nocarcinoma specimens obtained from all patients who 
underwent primary surgical treatment for cervical can-
cer between 1985 and 2005 with sufficient material avail-
able for analysis were obtained from the archives of the 
Department of Pathology, Leiden University Medical 
Center (n = 67). Cervical adenocarcinoma was defined as 
an invasive epithelial tumor showing glandular differentia-
tion (moderate to highly differentiated) or staining Peri-
odic Acid Schiff Plus and Alcian blue positive and lacking 
squamous elements (undifferentiated) [27, 28]. None of the 
patients had received preoperative anticancer therapy, and 
follow-up data were obtained from patient medical records. 
Patient and tumor characteristics are listed in Supplemen-
tary Table 1. Patient samples were handled according to the 
medical ethical guidelines described in the Code of Con-
duct for Proper Secondary Use of Human Tissue of the 
Dutch Federation of Biomedical Scientific Societies.
Immunofluorescent staining
Triple immunofluorescent staining was performed on 
4-μm-thick FFPE sections. After antigen retrieval using 
Tris–ethylenediaminetetraacetic acid (EDTA) buffer 
(10 mM Tris plus 1 mM EDTA pH 9.0), rabbit anti-CD3 
(ab828, Abcam, Cambride, UK), mouse IgG1 anti-FoxP3 
(ab20034, Abcam) and goat anti-IL-17 (AF-317-NA, 
R&D Systems, Abingdon, UK) diluted in 1 % w/v bovine 
serum albumin (BSA) in phosphate-buffered saline (PBS) 
were incubated at room temperature overnight. Alexa 
Fluor labeled donkey anti-rabbit-A546 (A10040), donkey 
anti-mouse-A647 (A31570) and donkey anti-goat-A488 
(A11055; all from Invitrogen, Life Technologies, Carlsbad, 
USA) were incubated at room temperature for 1 h. Slides 
were mounted using VectaShield mounting medium con-
taining DAPI (Vector Laboratories, Burlingame, USA). For 
negative controls, the primary antibodies were omitted and 
substituted with antibodies of the same isotype class with 
an unknown specificity.
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Microscopic analyses
Immunofluorescent images were acquired with an LSM700 
confocal laser scanning microscope equipped with an 
LCI Plan-Neofluar 25x/0.8 Imm Korr DIC M27 objective 
(Zeiss, Göttingen, Germany). In the majority of cases, four 
random images were obtained at a 250× magnification, 
sampling a total tumor area of generally 1.0 mm2, compris-
ing vital areas of both tumor epithelium and stroma. Double 
or triple positivity of cells as well as the tumor epithelium 
and stroma area were determined using the overlay tool 
in the LSM Image Browser software (version 4.2.0.121, 
Zeiss). The numbers of single, double and triple positive 
cells were scored in the tumor epithelium and tumor stroma 
separately using the open source image processing program 
ImageJ version 1.47 (http://rsb.info.nih.gov/ij). Cells within 
blood vessels or lumina were not counted.
Statistical analysis
Statistical analyses were performed using SPSS version 
20.0 (IBM Corp., Armonk, USA). Correlations between the 
number of positive cells and clinicopathological variables 
were tested using the Spearman’s rank correlation rho (r) 
and Wilcoxon Mann–Whitney tests. Correlations between 
the number of positive cells and disease-specific or dis-
ease-free survival were tested using the Kaplan–Meier and 
Cox proportional hazards models. For survival analyses, 
patients were divided in two groups based on the median 
numbers of positive cells (high and low). All tests were 




The cell density for all cell types analyzed was higher in the 
tumor stroma than in the epithelium (Fig. 1). Tumor infiltra-
tion by CD3+ T cells was observed in all samples analyzed, 
while only a minor population of Th17 cells was observed 
(Supplementary Fig. 1, Supplementary Table 2). FoxP3+ 
cells were always positive for CD3. Since a single FoxP3+ 
Fig. 1  Representative image of 
a cervical adenocarcinoma spec-
imen stained by triple immu-
nofluorescence for IL-17 (a), 
CD3 (b) and FoxP3 (c), with the 
combined staining together with 
DAPI counterstain (gray) shown 
in (d). The arrow indicates a 
cell double positive for IL-17 
and CD3. Different CD3/FoxP3 
double positive cells are present
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IL-17+ cell was only observed in two tumor samples (0.02 % 
of FoxP3+ cells), these cells were not further analyzed. 
Although approximately three times more CD3+ T cells and 
four times more (non-Th17) IL-17+ cells were present in 
the tumor stroma compared with the epithelium, especially 
Tregs were more strongly represented in the tumor stroma 
with on average over ten times higher cell counts.
Correlation between infiltrating immune cells 
and survival
A high total number of T cells were significantly correlated 
with improved disease-specific (p = 0.010, Fig. 2a) and 
disease-free survival (p = 0.001, Fig. 2d). This was specifi-
cally due to a high number of CD3+FoxP3+ Tregs, since a 
high number of CD3+FoxP3− T cells were less strongly 
correlated with disease-free survival (p = 0.032, Fig. 2f) 
than a high number of Tregs (p = 0.007, Fig. 2e). More 
importantly, there was no significant correlation between a 
high number of CD3+FoxP3− T cells and disease-specific 
survival (p = 0.254, Fig. 2c), but high Tregs were signifi-
cantly correlated with improved disease-specific survival 
(p = 0.010, Fig. 2b). Additionally, a high number of total 
CD3+ T cells within the tumor epithelium were signifi-
cantly correlated with improved disease-free (p = 0.034, 
Fig. 3d) but not with disease-specific survival (p = 0.248, 
Fig. 3a). These correlations were practically similar for the 
number of CD3+FoxP3− T cells (Fig. 3c, f), because the 
number of FoxP3+ cells infiltrating in the tumor epithelium 
was relatively low. The number of Tregs in the tumor epi-
thelium was not significantly correlated with disease-free 
or disease-specific survival (Fig. 3b, e). The separate analy-
ses of the correlation between the other cell types present 
in the tumor epithelium or the tumor stroma compartment 
and survival were not significant.
A high number of (non-Th17) IL-17+ cells per se were 
not significantly correlated with survival. However, when 
combining the Treg and IL-17 scores, patients could be bet-
ter categorized in groups with poor or improved survival. 
Compared with a high number of Tregs and a low Treg num-
ber but high IL-17+ cells, the combination of a low number 
of both Tregs and IL-17+ cells was correlated with worse 
disease-specific survival (p = 0.007, Fig. 4a). Since a high 
number of Tregs were correlated with favorable prognosis, 
the number of IL-17+ cells did not discriminate between 
patients with poor or improved survival in this patient group. 
Having a low number of Tregs and Th17 cells present was 
correlated with worse survival than high Tregs or low num-
bers of Tregs and the absence of Th17 cells (p = 0.018, 
Fig. 4b). So despite the generally low numbers of Th17 cells 
present, their presence still contributed to the effect of the 
number of Tregs present. Both correlations were also signifi-
cant for disease-free survival (data not shown).
Hazard ratio for low Tregs and IL‑17+ cells infiltration
The hazard ratio for disease-specific survival in case of 
a low number of Tregs was 9.38 (95 % CI 1.17–75.09, 
Fig. 2  Kaplan–Meier survival curves for a high versus low number of total CD3+ T cells (a, d), CD3+FoxP3+ Tregs (b, e) and CD3+FoxP3− T 
cells (c, f) are shown for disease-specific (a–c) and disease-free survival (d–f)
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p = 0.035, Table 1). This remained significant when cor-
recting for tumor lymph node metastasis (TNM) stage. The 
hazard ratio for disease-specific survival for tumors with 
a low number of both Tregs and IL-17+ cells was 13.91 
(95 % CI 1.67–115.73, p = 0.015, Supplementary Table 3) 
when compared with a high number of Tregs, which also 
remained significant after correcting for TNM stage. A 
low number of Tregs combined with the presence of Th17 
cells gave a hazard ratio of 12.83 (95 % CI 1.43–114.93, 
p = 0.023, Supplementary Table 4) when compared with 
a high number of Tregs or low Tregs and absence of Th17 
cells, also still significant after correcting for TNM stage.
Fig. 3  Kaplan–Meier survival curves for a high versus low number of CD3+ cells (a, d), CD3+FoxP3+ Tregs (b, e) and CD3+FoxP3− T cells (c, 
f) infiltrating in the tumor epithelium (IE) are shown for disease-specific (a–c) and disease-free survival (d–f)
Fig. 4  Kaplan–Meier survival 
curves for disease-specific 
survival based on a high number 
of Tregs compared with a low 
number of Tregs combined with 
high or low IL-17+ cells (a) or 
the absence or the presence of 
Th17 cells (b)
Table 1  Hazard ratio for a low Tregs frequency
Univariate and multivariate Cox regression analyses for the TNM stage and a low number of Tregs on disease-specific survival are shown. The 
95 % confidence interval (95 % CI) of the hazard ratio is indicated within parentheses
Variable Univariate Cox regression Multivariate Cox regression
Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value
TNM stage 1.606 (1.133–2.276) 0.008 1.643 (1.144–2.361) 0.007
Tregs low 9.384 (1.173–75.093) 0.035 10.131 (1.256–81.719) 0.030
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Correlation between IL‑17+ cells 
and clinicopathological parameters
Finally, we investigated whether the different cell popula-
tions were associated with prognostic clinicopathological 
parameters (lymph node metastasis, tumor size, vaso-inva-
sion and infiltration depth). A high number of IL-17+ cells 
were significantly correlated with the absence of vaso-inva-
sion (p = 0.001, Fig. 5a), decreased tumor infiltration depth 
(r = −0.29, p = 0.021, Fig. 5b) and decreased tumor size 
(r = −0.28, p = 0.030, Fig. 5c). No other significant cor-
relations were found.
Discussion
The current study showed that a high total number of Tregs 
were significantly correlated with improved disease-free 
and disease-specific survival in cervical adenocarcinoma 
patients. Although tumor-infiltrating immune cells are 
more frequently present in tumor stroma than in tumor epi-
thelium, especially Tregs were about three times less fre-
quently present in the tumor epithelium than T cells and 
IL-17+ cells. Within the tumor epithelium, a high T cell 
frequency was significantly correlated with improved dis-
ease-free survival. Strikingly, specifically a low total num-
ber of both Tregs and IL-17+ cells were strongly correlated 
with poor survival. The IL-17+ cells were inversely corre-
lated with vaso-invasion, tumor size and infiltration depth. 
The number of IL-17+ cells could thus further discriminate 
between patient prognoses after Treg determination. In 
addition, a low number of Tregs combined with the pres-
ence of Th17 cells were correlated with worse prognosis.
The current data suggest that, of the immunological 
parameters studied, the total number of Tregs is the most 
important determinant correlated with survival for cervi-
cal adenocarcinoma patients. Tregs thus seem to represent 
a beneficial immune response in cervical adenocarcinoma, 
which contrasts Tregs correlating with poor survival in 
cervical squamous cell carcinoma [25, 29]. This corre-
sponds with studies that indicate that cervical adenocarci-
noma differs substantially from squamous cell carcinoma 
[13–15, 24] and suggests that the composition and effect 
of the tumor-infiltrating immune cells differ per histologi-
cal tumor subtype. However, a direct correlation between 
total Tregs and survival in cervical squamous cell car-
cinoma has not been shown: the significant correlations 
were specifically found within the tumor epithelium and 
especially when compared with the number of cytotoxic 
T cells present. A specific correlation between a high ratio 
of total T cells or CTL over Tregs and improved survival 
has recently also been shown in glioblastoma [30]. When 
we studied the tumor epithelium separately, total T cell fre-
quency was correlated with improved disease-free survival. 
The latter correlation was irrespective of Tregs, because 
the intraepithelial T cell frequency predominantly com-
prised FoxP3− cells. Thus, intraepithelial T cell infiltrate 
seems to be a general marker for improved survival. These 
intraepithelial T cells might predominantly be cytotoxic 
T lymphocytes (CTL). Another partial explanation for the 
differences found between the histological subtypes might 
be that the tumors of this cervical adenocarcinoma cohort 
were generally smaller in size than the squamous cell carci-
nomas, as was described before [27]. Supporting our data, 
other studies have also reported correlations between Tregs 
and poor survival [31–33], indicative of the dampening of 
an anti-tumor immune response. However, Tregs have also 
been found to be correlated with improved prognosis in dif-
ferent types of cancer [34–37], suggesting that they may 
also dampen a tumor-promoting immune response. Indeed, 
the role of Tregs in cancer is controversial and seems to be 
context and tumor type dependent [38]. The current data 
support a predominant role in suppressing tumor growth, 
favoring inflammation in cervical adenocarcinoma.
Fig. 5  Correlation between the number of total non-Th17 IL-17+ 
cells and vaso-invasion is shown in a. The p value was calculated 
using the Wilcoxon Mann–Whitney test. The correlations between the 
number of non-Th17 IL-17+ cells and the continuous variables tumor 
infiltration depth (b) and tumor size (c) were calculated using the 
Spearman’s rank correlation rho test
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IL-17 has, in general, been shown to correlate with poor 
survival, and Th17 cells with improved survival in can-
cer [39]. The pro-inflammatory cytokines IL-6 and IL-23, 
which are implicated in the induction of IL-17 expression 
[40], have also been shown to be correlated with poor sur-
vival in cervical cancer [41]. Since IL-17 has been shown 
to be generally expressed by granulocytes [26], this sug-
gests that a pro-inflammatory environment may attract 
granulocytes and other innate myeloid cells favoring tumor 
growth in cervical squamous cell carcinoma. The correla-
tion between increased IL-17+ cells and improved sur-
vival especially in case of low Treg frequencies in cervi-
cal adenocarcinoma suggests that these cells might rather 
counteract tumor growth in cervical adenocarcinoma. We 
have previously shown that IL-17-producing cells represent 
a heterogenous cell population [26], and we propose that 
IL-17+ cells may predominantly represent tumor-target-
ing myeloid cells in cervical adenocarcinoma, potentially 
mast cells and type 1 neutrophils and macrophages. Corre-
spondingly, Chen et al. [42] showed that a high number of 
infiltrating IL-17+ cells were significantly correlated with 
improved survival in a large cohort of gastric adenocarci-
noma patients.
Our results showed that the presence of Th17 cells, spe-
cifically when a low number of Tregs were present, was 
correlated with poor survival. A pro-inflammatory Th17 
response, despite the low frequencies, might thus rather be 
correlated with a tumor-promoting immune response. This 
does correspond with a study by Yan et al. [43], showing 
that an increased frequency of circulating Th17 cells is cor-
related with poor survival in hepatocellular cancer. Also 
this correlation is in contrast with its role in a beneficial 
immune response in cervical squamous cell carcinoma [26] 
as well as other cancer types [39].
These different correlations suggest that the local 
immune response in cervical adenocarcinoma differs sub-
stantially from the immune response in squamous cell 
carcinoma. This might be related to differences in the 
molecular constitution of the two cancer types. Cervical 
adenocarcinoma has recently been shown to contain more 
frequent TP53 [44] and KRAS mutations and less frequent 
PIK3CA and PTEN mutations compared with squamous 
cell carcinoma [45]. In our patient cohort, we found sig-
nificantly more frequent somatic KRAS mutations in cer-
vical adenocarcinoma, whereas PIK3CA mutations were 
more frequently found in squamous cell carcinoma (man-
uscript submitted). We have furthermore shown that CXC 
chemokine receptor 4 (CXCR4), CXCR7 and epider-
mal growth factor receptor (EGFR) were more frequently 
expressed in cervical squamous cell carcinoma than ade-
nocarcinoma [46]. Additionally, we showed that HLA-E 
was overexpressed more frequently in cervical adenocar-
cinoma than squamous cell carcinoma [27]. High HLA-E 
expression was significantly correlated with improved 
disease-free and disease-specific survival in cervical adeno-
carcinoma, while no correlation was found in squamous 
cell carcinoma. Cervical adenocarcinoma samples have 
also been shown to produce higher levels of transforming 
growth factor-β (TGF-β) than squamous cell carcinoma 
samples [24]. Since we showed in the present study that 
Tregs, Th17 cells and other IL-17+ cells also show opposed 
correlations in cervical adenocarcinoma than in squamous 
cell carcinoma, this suggests that the molecular differences 
are correlated with a different type of immune response. 
We speculate that the increased HLA-E and TGF-β expres-
sion might cause an effector T cell response to have limited 
efficacy. Under these circumstances, classically activated 
myeloid cells such as type 1 neutrophils might be more 
effective in cervical adenocarcinoma. Infiltration of T cells 
into the tumor epithelium was correlated with improved 
survival in both cervical cancer types.
To conclude, our data show that the role of T cells, 
including Tregs, Th17 cells and other IL-17+ cells, is con-
text and tumor type dependent. Tregs and IL-17+ cells 
represented a beneficial immune response correlated with 
improved survival, while Th17 cells might contribute to 
tumor progression and poor prognosis in cervical adenocar-
cinoma. Future research should determine how these cell 
types are correlated with improved prognosis, what other 
immune cell types are involved and how this might be used 
to guide patient prognosis and treatment.
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